MGTA News and Press, Magenta Therapeutics Inc. From 02/20/20

-- Additional data from Phase 2 study show that MGTA-456 demonstrates clinically meaningful durable benefits for patients with inherited metabolic disorders one year following treatment – -- Magenta intends to complete enrollment in Phase 2 in 2020 and continue dialogue with the...

The following slide deck was published by Magenta Therapeutics, Inc. in conjunction with this Read more ...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks Oncology ...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the expansion of its senior leadership with two new strategic hires, Kristen Stants as Chief People Officer ...

New MGTA-117 ADC clinical candidate for conditioning demonstrates broad therapeutic index; advancing MGTA-117 to generate initial patient clinical data in 2021 MGTA-145 first-line stem cell mobilization agent on track to complete Phase 1 study and move into multiple Phase 2 studies ...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Wat...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company is scheduled to present at the 38 th Annual J.P. Morgan Healthcare Conference in San Franc...

The following slide deck was published by Magenta Therapeutics, Inc. in conjunction with this Read more ...

Thinly traded Magenta Therapeutics ( MGTA +14.7% ) is up more than double normal volume, albeit on turnover of only 211K shares, on the heels of encouraging preclinical data on CD117-ADC, its most advanced program for the preparation of patients undergoing stem cell transplantation or ge...